

Rec'd PTO 08 JUL 2005 10/522232

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/522,232 Confirmation No. : 1644
First Named Inventor : Bradley MCCOLL
Filed : January 24, 2005
TC/A.U. : To Be Assigned
Examiner : To Be Assigned
Docket No. : 029065.51433US
Customer No. : 23911
Title : Methods and Compositions for Activating or Inhibiting VEGF-D and VEGF-C

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

Copies of the references listed on the attached form PTO-1449 have already been provided by the International Searching Authority, therefore, duplicate copies are not attached hereto. Applicant encloses herewith a copy of a corresponding International Search Report dated October 8, 2004, citing such documents indicating the degree of relevance found by the foreign office.

The present Information Disclosure Statement is being filed (1) no later than three months from the application's filing date or (2) before the mailing date of the first Office Action on the merits (whichever is later), and therefore no certification under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

If necessary, the paper should be considered as a petition for consideration of the Information Disclosure Statement under 37 C.F.R. § 1.97(d)(1) and that the petition fee set forth in 37 C.F.R. § 1.17(p) in accordance with 37 C.F.R. § 1.97(d)(2) should be charged to Deposit Account 05-1323, Attorney Docket No.: 029065.51433US.

Respectfully submitted,

July 8, 2005



Kening Li
Registration No. 44,872

CROWELL & MORING LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
JDE:KLI:lvb
384734

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	1	Application Number	10/522,232
				Filing Date	January 24, 2005
				First Named Inventor	Bradley MCCOLL
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
				Attorney Docket Number	029065.51433US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		OLOFSSON et al., Proc. Natl. Acad. Sci. USA, September 1998, Vol. 95, pages 11709-11714, especially abstract and page 11712, column 1, paragraph 2.	
		PLOUET et al., J. Biol. Chem., May 1997, Vol. 272, No. 20, pages 13390-13396, especially abstract and page 13393.	
		STACKER et al., J. Biol. Chem., November 1999, Vol. 274, No. 45, pages 32127-32136, especially abstract, page 32127, column 2 to page 32128, paragraph 1, and page 32130.	
		ENHOLM et al., Trends in Cardiovascular Medicine, 1998, Vol. 8, No. 7, pages 292-297, especially Figure 2 at page 294.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.